Impact of HLA-DPB1 Matching in Unrelated Allogeneic Stem Cell Transplantation: Results of Two Centers From Turkey

Kantarcioglu B., Bekoz H. S., Hindilerden I. Y., Kivanc D., Ogret Y., Besisik S., ...More

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.27, no.2, pp.74-84, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 2
  • Publication Date: 2017
  • Doi Number: 10.4999/uhod.171736
  • Journal Name: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.74-84
  • Keywords: Allogeneic stem cell transplantation, GVHD, Human leukocyte antigen, HLA-DPB1, VERSUS-HOST-DISEASE, BONE-MARROW-TRANSPLANTATION, DP-BETA ALLELE, HLA-DP, MISMATCH, IMMUNOTHERAPY, DISPARITY, SURVIVAL, RISK, MORTALITY
  • Istanbul University Affiliated: Yes

Abstract

In this study, we retrospectively examined 34 donor/recipient transplant pairs fully tested for the alleles HLA-A, B, C, DRB1, DQB1 and DPB1 in two different centers in Istanbul, Turkey. HLA-DPB1 disparity in at least one antigen level was 79.6% and only 20.6% of transplant pairs were fully identical for HLA-DPB1, in our study group. Neutrophil and thrombocyte engraftment successfully occurred in the entire study group. When the occurrence of severe (Grade III-IV) aGVHD was taken into account, we have observed that, non-permissive HLA-DPB1 mismatches were a significant factor for development of severe aGVHD (p= 0.019). There was a trend of increasing significance for the gut (p= 0.006) and liver (p: 0.054) aGVHD but not for skin aGVHD in non-permissive HLA-DPB1 mismatched transplantations. In multivariate analysis, non-permissive HLA-DPB1 mismatches remained as an independent factor for severe aGVHD. Our results did not show a significant impact of HLA-DPB1 mismatches on relapse. In survival analysis, both HLA-DPB1 disparities and non-permissive mismatches showed a decreasing trend of event free and overall survival times. Considering these results during donor selection may improve transplant outcomes in the setting of unrelated ASCT.